Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)

Market Cap	2.06B -2.9%
Revenue (ttm)	187.02M +10.0%
Net Income	-80.52M
EPS	-0.84
Shares Out	95.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	128,537
Average Volume	177,707
Open	21.55
Previous Close	21.50
Day's Range	21.00 - 22.00
52-Week Range	20.55 - 33.65
Beta	0.14
RSI	38.74
Earnings Date	May 14, 2026

About TPEX:6704

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 55
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6704

Financial Performance

In 2025, TPEX:6704's revenue was 187.02 million, an increase of 10.00% compared to the previous year's 170.03 million. Losses were -80.52 million, -3.36% less than in 2024.